Do You Need a Duplex Scan Before Microsclerotherapy? A Review of the Evidence

By Dr. Haroun Gajraj | VeinCare Academy | 10th June 2026

This review is written for healthcare professionals who perform Microsclerotherapy of leg telangiectasia. It examines the published evidence and international guideline positions on whether Duplex Ultrasound Scanning (DUS) should be performed routinely before treatment, and proposes a practical selective screening policy.

Contents

1. Introduction

2. The case for routine duplex scanning before Microsclerotherapy treatment of leg spider veins (Telangiectasia)

3. What the guidelines actually say

4. The evidence problem: does DUS improve outcomes?

5. Reflux prevalence in C1 disease: what we know

6. A practical selective screening policy

7. When reflux is found: what then?

8. Key clinical points

9. References

🎥 Prefer video? Watch the full review on YouTube: "Do You NEED a Duplex Ultrasound Before Microsclerotherapy for spider veins? (What the Evidence Says)" [→click here]

1. Introduction

Microsclerotherapy is the first-line treatment for CEAP C1 disease: telangiectasias and reticular veins. It is effective, widely available, and when performed carefully, very well tolerated.

One question divides opinion more than almost any other in this field: should every patient presenting for microsclerotherapy of cosmetic thread veins first undergo duplex ultrasound scanning to look for underlying venous reflux?

On current evidence, and in line with recent international guideline positions, routine duplex ultrasound scanning is not justified for every patient presenting with asymptomatic C1 disease.

This does not mean duplex scanning is not important. It means that selective, clinically guided use of DUS is appropriate and supported by current evidence. And I will explain why.

2. The Case for Routine Duplex Scanning Before Microsclerotherapy Treatment of Legs Spider Veins (Telangiectasia)

The traditional argument for mandatory pre-treatment DUS goes as follows. Telangiectasias arise, at least in part, from venous hypertension transmitted from incompetent proximal venous segments: saphenous trunks, reticular feeding veins, or perforating veins. If you treat the surface without addressing the haemodynamic source, the results will be short-lived and recurrence will be more frequent.

It sounds intuitive. 

Duplex studies do show that saphenous incompetence is common in C1 limbs; around 44% in referral populations in one prospective study of 1,386 limbs (Hong, 2022). The Edinburgh Vein Study found a statistically significant trend for increasing superficial incompetence with worsening telangiectasia grade.

A small study (Schuller-Petrovic et al., 2013) found that in 26 patients with telangiectasia resistant to repeated courses of sclerotherapy, 65% had a demonstrable connection to deeper or perforating vessels on ultrasound. Ultrasound-guided injection into the feeding vein achieved clearance in those cases.

At face value, this could be taken as an argument for scanning everyone. However, there are several important limitations to that interpretation.

3. What the Guidelines Say

The guideline advice is not uniform.

It is worth understanding where the key bodies stand and how strong the evidence behind each position is.

The ESVS 2022 Guidelines recommend DUS before treating all patients with reticular veins and telangiectasias, and advise that significant incompetent veins should be treated before addressing smaller ones. This appears to settle the question. However, both recommendations are based largely on expert consensus rather than direct outcome data (level C evidence).

The UIP Microsclerotherapy Guidelines (2024): authored specifically for C1 disease, these  take a different view: "If C1 disease is not accompanied with symptoms consistent with venous disease, duplex ultrasound is not required and investigation of abnormal venous haemodynamics with duplex ultrasound should be reserved for symptomatic patients only."

The SVS/AVF/AVLS 2023 Clinical Practice Guidelines: the product of independent systematic reviews and meta-analyses, representing the highest methodological standard in venous guideline development, these explicitly recommend against routine DUS in asymptomatic C1 patients, and add a direct warning: routine scanning "could result in unnecessary saphenous vein ablation procedures."

NICE CG168 (2013, surveillance updated 2016) examined whether DUS improves outcomes from venous interventional treatment. The response was unambiguous: "No relevant evidence identified."

The divergence between ESVS and UIP/SVS/AVF/AVLS matters. The ESVS recommendation, however compelling it sounds in principle, rests on expert consensus rather than clinical outcome data. The UIP and American guidelines interpret the same limited evidence base differently, placing greater weight on selectivity and on the risk of over-investigation and overtreatment.

4. The Evidence Problem: Does DUS Improve Outcomes after Microsclerotherapy?

This is the central question, and the evidence is strikingly thin.

No randomised controlled trial and no adequately powered observational study has directly compared microsclerotherapy outcomes in patients who had pre-treatment DUS with those who did not.

The EASI study (Rabe et al., 2010), one of the best RCTs of sclerotherapy for telangiectasia, achieved a physician-assessed improvement rate of 96% at week 12 and 95% at week 26, with patient satisfaction of 84–88%. Pre-treatment DUS was not mandated. The haemodynamic status of the saphenous system in those patients was not a condition of entry or a modifier of outcome.

A Cochrane systematic review of treatments for telangiectasia and reticular veins (Nakano et al., 2021) found no evidence that any treatment modality was superior for resolution, and did not identify duplex status as a modifier of treatment outcome.

The key question, whether identifying and treating underlying reflux before microsclerotherapy improves cosmetic outcomes or reduces recurrence, remains unanswered by primary clinical data. The rationale is intuitive, but it has not been proven.

That gap in evidence is one reason why guideline recommendations diverge despite reviewing broadly similar literature.

The UIP guideline explicitly acknowledged this gap, calling for prospective comparative trials to determine "if routine duplex scan for underlying reflux is required in all presentations" of C1 disease. Those trials have not yet been done.

5. Reflux Prevalence in C1 Disease: What Current Evidence Shows

Understanding the epidemiology helps calibrate the clinical decision.

• The Edinburgh Vein Study found that 84% of the general population has some degree of telangiectasia. Among those with grade 2–3 telangiectasia, 51% had no clinical evidence of varicose veins. Telangiectasia and truncal venous incompetence are associated but frequently dissociated.

• The association between telangiectasia severity and venous reflux in the Edinburgh Vein Study, whilst statistically significant, was described by the authors as "not wholly consistent." Small saphenous incompetence showed no significant association with increasing telangiectasia grade.

• The study showing 44% prevalence of saphenous incompetence in C1 limbs (Hong, 2022) was conducted in a vascular surgery referral population and it may have included more haemodynamic disease compared with a general aesthetic clinic population.

• The pathophysiology of telangiectasia is multifactorial. Kern's systematic review (2018) concluded that arterio-venous micro-shunts, parietal and connective tissue abnormalities all contribute alongside reflux, and that the precise mechanisms are "still largely unknown."

  
  This does not diminish the relevance of reflux. It means that treating underlying reflux will not solve the problem in every case, and that assuming reflux is the cause in every case is an oversimplification.

6. A Practical Selective Screening Policy

Based on current evidence and the positions of the UIP and SVS/AVF/AVLS, the following framework is a pragmatic approach to everyday clinical practice.

DUS is typically not required before Microsclerotherapy when

• The patient presents with isolated telangiectasia or reticular veins (CEAP C1) and no venous symptoms

• No palpable varicose veins on examination

• No ankle or lower limb swelling

• No skin changes (pigmentation, lipodermatosclerosis, varicose eczema, atrophie blanche)

• No history of venous ulceration or deep vein thrombosis

• The presentation is purely cosmetic

DUS should be performed before Microsclerotherapy when

• Symptoms consistent with venous disease: aching, heaviness, throbbing, burning, cramps, or restless legs

• Visible varicose veins in addition to telangiectasia (suggesting C2 or higher disease)

• Ankle or lower limb oedema

• Skin changes: hyperpigmentation, varicose eczema, lipodermatosclerosis, or atrophie blanche

• Corona phlebectatica (fan-shaped telangiectasia around the medial malleolus)

• Previous venous interventions: stripping, ablation, prior sclerotherapy

• History of DVT or post-thrombotic syndrome

• Telangiectasia resistant to previous courses of sclerotherapy

• Clinical suspicion of pelvic venous origin (perineal or thigh distribution)

This approach is consistent with current evidence, practical, and applicable in both vascular and aesthetic settings. It does not require DUS for straightforward cosmetic cases and provides clear indications for scanning where clinical features raise the index of suspicion.

7. When Reflux Is Found: What Then?

Not all detected reflux requires treatment before Microsclerotherapy. This is a point that is often overlooked.

The UIP guideline's position is nuanced: where reflux is identified in a venous segment not involved with the C1 disease, "elimination of reflux may not be necessary" and a shared decision-making approach should be used. Where reflux is symptomatic and clearly driving the presentation, addressing it first makes clinical sense. 

But the cascade from DUS detection of asymptomatic reflux to saphenous ablation in a patient who came for cosmetic thread vein treatment carries its own risks, costs, and potential harms.

Cho et al. (2023) studied 46 patients with symptomatic C1 disease and confirmed saphenous reflux. Both conservative management and endovenous ablation led to significant clinical improvement at 6 months, with no statistically significant difference in overall outcome for most patients. The implication: even when reflux is present and symptomatic, the treatment pathway is not automatically clear-cut.

8. Key Clinical Points

• Routine DUS before microsclerotherapy of asymptomatic telangiectasia is not currently supported by primary clinical outcome data, and is not recommended by the UIP (2024) or SVS/AVF/AVLS (2023).

• The ESVS (2022) recommends universal DUS at Level C evidence only: expert consensus, not primary trial data.

• NICE found "no relevant evidence" that DUS improves venous treatment outcomes.

• The EASI study reported very high improvement rates for Microsclerotherapy  (as assessed by the physician) without mandatory pre-treatment DUS.

• Underlying reflux is common in C1 limbs (~44% in referral populations) but not universal, and the pathophysiology of telangiectasia is multifactorial.

• Selective DUS, guided by symptoms and clinical signs, is a pragmatic approach which is consistent with current evidence. 

• Duplex ultrasound scan is indicated in cases where telangiectasia are resistant to Microsclerotherapy.

• When reflux is found, treatment decisions should be individualised; not all detected reflux requires ablation before microsclerotherapy.

• There is a strong need for a well-designed prospective comparative trial of microsclerotherapy outcomes with and without prior reflux identification and treatment.

For uncomplicated asymptomatic C1 disease, duplex is usually selective rather than routine. Scan when symptoms, clinical signs, previous venous disease, or treatment resistance raise suspicion of clinically relevant reflux.

9. References

1. Tan M, Shaydakov E, Parsi K, Davies AH; on behalf of the International Union of Phlebology. Microsclerotherapy: International Union of Phlebology One-Page Guidelines. Phlebology. 2024;39(4):280–283. https://pubmed.ncbi.nlm.nih.gov/38103047/
   

2. Ruckley CV, Evans CJ, Allan PL, Lee AJ, Fowkes FGR. Telangiectasia in the Edinburgh Vein Study: epidemiology and association with trunk varices and symptoms. Eur J Vasc Endovasc Surg. 2008;36(6):719–724. https://pubmed.ncbi.nlm.nih.gov/18848475/
   

3. Nakano LCU, Cacione DG, Baptista-Silva JC, Flumignan RLG. Treatment for telangiectasias and reticular veins. Cochrane Database Syst Rev. 2021;10(10):CD012723. https://pubmed.ncbi.nlm.nih.gov/34637138/
   

4. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. 2010;25(3):124–131. https://pubmed.ncbi.nlm.nih.gov/20483861/
   

5. Kern P. Pathophysiology of telangiectasias of the lower legs and its therapeutic implication: a systematic review. Phlebology. 2018;33(4):225–233. https://pubmed.ncbi.nlm.nih.gov/29388868/
   

6. Schuller-Petrovic S, Pavlovic MD, Schuller S, Schuller-Lukic B, Adamic M. Telangiectasias resistant to sclerotherapy are commonly connected to a perforating vessel. Phlebology. 2013;28(6):320–323. https://pubmed.ncbi.nlm.nih.gov/22865418/
   

7. Hong KP. Correlation of clinical class with duplex ultrasound findings in lower limb chronic venous disease. J Chest Surg. 2022;55(3):233–238. https://pubmed.ncbi.nlm.nih.gov/35478179/
   

8. Ruckley CV, Allan PL, Evans CJ, Lee AJ, Fowkes FGR. Telangiectasia and venous reflux in the Edinburgh Vein Study. Phlebology. 2012;27(6):297–302. https://pubmed.ncbi.nlm.nih.gov/22106449/
   

9. Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 SVS/AVF/AVLS clinical practice guidelines for the management of varicose veins. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. https://pubmed.ncbi.nlm.nih.gov/37652254/
   

10. De Maeseneer MG, Kakkos SK, Aherne T, et al. ESVS 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://pubmed.ncbi.nlm.nih.gov/35027279/
    

11. National Institute for Health and Care Excellence. Varicose Veins in the Legs. Clinical Guideline CG168. 2-Year Surveillance Update 2016. https://www.nice.org.uk/guidance/cg168/evidence/appendix-a-decision-matrix-pdf-2307804014
    

12. Cho A, Ahn S, Mo H, Min SK, Jung IM. Treatments for symptomatic class I patients in CEAP classification with saphenous vein reflux: a pilot study. J Vasc Surg Venous Lymphat Disord. 2023;11(4):700–707. https://pubmed.ncbi.nlm.nih.gov/37030448/
    

About the Author

This educational article is written and regularly reviewed by Dr Haroun Gajraj, a GMC‑registered vein specialist who has treated thousands of patients with vein disease and has trained many doctors and nurses in microsclerotherapy, shortwave diathermy and related cosmetic vein procedures.

Dr Gajraj is the founder and board member of the British Association of Sclerotherapists.

You can view his current GMC registration and independent patient reviews on iWantGreatCare for further information about his clinical background. This is written for healthcare professionals and is based on current clinical guidelines, peer‑reviewed research and day‑to‑day practice experience. The information here is general education only and is not a substitute for individual clinical judgement, local protocols or formal training. Clinicians remain responsible for assessing each patient, obtaining informed consent, explaining risks and alternatives, and working within the scope of their professional registration and regulatory guidance.

Subscribe

For regular updates get my weekly newsletter here

© VeinCare Academy | Dr. Haroun Gajraj | veincare.academy This article is intended for qualified healthcare professionals. All clinical decisions should be based on individual patient assessment, primary medical literature, and current professional guidelines.